Trials / Completed
CompletedNCT00073112
A Study of ABT-751 in Patients With Renal Cell Cancer
A Phase 2 Study of ABT-751 in Subjects With Refractory Colorectal Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-751 |
Timeline
- Start date
- 2003-08-01
- Completion
- 2006-09-01
- First posted
- 2003-11-18
- Last updated
- 2007-11-29
Locations
23 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00073112. Inclusion in this directory is not an endorsement.